Login to Your Account

Clinic Roundup

Wednesday, July 18, 2012
• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said its safety monitoring committee meeting of July 12 was favorable and indicated no significant safety concerns for two pivotal U.S. trials testing NX-1207 in benign prostatic hyperplasia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription